Your browser doesn't support javascript.
loading
Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV-infected individuals.
Arab-Alameddine, M; Lubomirov, R; Fayet-Mello, A; Aouri, M; Rotger, M; Buclin, T; Widmer, N; Gatri, M; Ledergerber, B; Rentsch, K; Cavassini, M; Panchaud, A; Guidi, M; Telenti, A; Décosterd, L A; Csajka, C.
  • Arab-Alameddine M; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Lubomirov R; Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Fayet-Mello A; Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Aouri M; Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Rotger M; Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Buclin T; Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Widmer N; Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Gatri M; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Ledergerber B; Division of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • Rentsch K; Clinical Chemistry, University Hospital Basel, Basel, Switzerland.
  • Cavassini M; Division of Infectious Diseases, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Panchaud A; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Guidi M; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland.
  • Telenti A; Institute of Microbiology, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Décosterd LA; Clinical Pharmacology Laboratory, University Hospital and University of Lausanne, Lausanne, Switzerland.
  • Csajka C; School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland Division of Clinical Pharmacology, University Hospital Center and University of Lausanne, Lausanne, Switzerland chantal.csajka@chuv.ch.
J Antimicrob Chemother ; 69(9): 2489-98, 2014 Sep.
Article en En | MEDLINE | ID: mdl-24821595
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Infecciones por VIH / Ritonavir / Fármacos Anti-VIH Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Sulfonamidas / Infecciones por VIH / Ritonavir / Fármacos Anti-VIH Tipo de estudio: Prognostic_studies Límite: Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Año: 2014 Tipo del documento: Article